MCL1 and myeloid sarcoma: Given the central role of GR signaling in mediating clinical response to GC therapy in MS (via regulation of inflammation and apoptosis), in the present study we measured key GR-target genes such as GILZ, MCL-1 and NOXA in MS patients during relapse and evaluated whether any of the abovementioned genes could be considered as markers of the MP treatment response.